Atlas Trials

Predictive Value of Innovative Prognostic Markers (Gut Microbiota, Sarcopenia, Metabolic Syndrome and Obesity) on Surgical and Oncologic Results in the Management of Sporadic Colorectal Adenocarcinoma.

Clinical trial NCT03843905 · UNKNOWN

Trial details

NCT number
NCT03843905
Sponsor
University Hospital, Clermont-Ferrand
Status
UNKNOWN
Study type
OBSERVATIONAL
Colorectal NeoplasmsMicrobiotaPrognosisMetabolic SyndromeSarcopenia
Start date
2018-11-15
Primary completion
2018-11-15
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.